GSK-3 as a novel prognostic indicator in leukemia
1Department of Leukemia, Unit 448, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States.
Advances in Biological Regulation
|May 14, 2017
Summary
Glycogen Synthase Kinase 3 (GSK3) plays a dual role in leukemia, acting as both a tumor suppressor and promoter. Understanding its function is key to developing new leukemia therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Leukemias involve dysregulated signaling pathways affecting leukemogenesis, drug resistance, and leukemia stem cells.
- The AKT kinase, activated by mutations in upstream regulators, targets Glycogen Synthase Kinase 3 (GSK3).
- GSK3 isoforms are constitutively active and have emerged as key players in cancer.
Purpose of the Study:
- To review the dual role of GSK3 as a tumor suppressor and promoter in various leukemias.
- To discuss the implications of GSK3 activity in leukemia progression and survival.
- To briefly cover the current status of GSK3 inhibitors in leukemia therapy.
Main Methods:
- Literature review of studies on GSK3 function in leukemia.
- Analysis of signaling pathways involving AKT and GSK3.
- Examination of GSK3's role in targeting oncogenic and tumor suppressor proteins.
Main Results:
- Active GSK3 can suppress tumors by promoting the destruction of oncogenic proteins like beta Catenin, c-MYC, and MCL-1.
- GSK3 inactivation in Acute Myeloid Leukemia (AML) correlates with poor survival.
- In certain leukemias, GSK3 can promote tumors by targeting tumor suppressors, such as p27Kip1 in MLL-translocated AML.
Conclusions:
- GSK3 exhibits context-dependent roles in leukemia, acting as both a tumor suppressor and promoter.
- Further research into GSK3's complex functions is crucial for advancing leukemia treatment strategies.
- GSK3 inhibitors represent a potential therapeutic avenue for leukemia, warranting continued investigation.
